Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers
Clinical trial NCT01848756 · TERMINATED
Trial details
- NCT number
- NCT01848756
- Sponsor
- Esanex Inc.
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2013-04-01
- Primary completion
- 2015-02-01
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.